Achaogen Receives £4.1 Million Award from the Wellcome Trust to Advance Its Neoglycosides Portfolio

Achaogen, an emerging biopharmaceutical company addressing the issue of multi-drug resistant bacterial infections through the discovery and development of innovative broad-spectrum antibiotics, announced that it has received a £4.1 million Seeding Drug Discovery award from the Wellcome Trust. This award will help support the investigational new drug (IND)-enabling studies and advancement into clinical trials of Achaogen’s portfolio of proprietary neoglycosides for the treatment of Gram-negative bacterial infections. Neoglycosides are Achaogen’s unique, next-generation aminoglycosides, in development to address the growing issue of multi-drug resistance to antibiotic agents.

...

Want to see the full article?

• Purchase this article for only $3.00